Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1 12Phase 1/2 8Phase 3 7Phase NA 4Phase 4 3Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Leukemia 29Hematologic Neoplasms 23Myelodysplastic Syndromes 18Lymphoma 16Neoplasms 15Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 7Graft vs Host Disease 7Neoplasms by Site 6Neoplasms by Histologic Type 6Multiple Myeloma 6Anemia, Refractory, with Excess of Blasts 6Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Plasma Cell 5Neoplasm, Residual 5Leukemia, Biphenotypic, Acute 5Infections 5Primary Myelofibrosis 4Lymphoproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Glioma 4Congenital Abnormalities 4

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Bronchiolitis Obliterans Syndrome × Other hematologic neoplasm × Clear all
NCT00349518 2016-02-17

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Bristol-Myers Squibb

Phase 2/3 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡